⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38738 | 1.00 | — | — | |
| Bicarbonate SCHEMBL746393 | 0.88 | ALDH1A1 (0.40) | — | |
| SCHEMBL31490392 | 0.80 | — | — | |
| SCHEMBL111337 | 0.80 | — | — | |
| SCHEMBL29367162 | 0.80 | — | — | |
| SCHEMBL1255843 | 0.80 | — | — | |
| Trifluoroacetic Acid SCHEMBL4114425 | 0.79 | JUN (0.39) | — | |
| SCHEMBL14844352 | 0.79 | LMNA (0.41) | — | |
| Ammonia Solution, Strong SCHEMBL25301697 | 0.77 | — | — | |
| SCHEMBL16305172 | 0.77 | ALDH1A1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4634195-A1 | PROCESS FOR THE PREPARATION OF RELUGOLIX | Medichem, S.A. (ES) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025217336-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024126674-A1 | PROCESS FOR THE PREPARATION OF RELUGOLIX | MEDICHEM, S.A. (ES) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| EP-4003988-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | disclosed |